Clinical Trial Update: An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) [Phase 3]

View source ↗

Summary

Open-label extension study to assess long-term safety and tolerability of Pelacarsen (TQJ230) in hyperlipoproteinemia(a) patients; Phase 3, currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipoproteinemia

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hyperlipoproteinemia (a) | Phase 3 | Status: ACTIVE_NOT_RECRUITING